FDA Approves Enfortumab Vedotin-Ejfv for Urothelial Cancer

The FDA has granted regular approval to enfortumab vedotin-ejfv (Padcev®, Astellas Pharma US, Inc.) for patients with locally advanced or metastatic urothelial cancer who have previously received a programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy or those who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. "Patients with locally advanced or metastatic ur...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.